Tempest Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
Mailing Address 2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
Phone 415-798-8589
Fiscal Year End 1231
EIN 451472564
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | February 10, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 3 Initial insider ownership report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 8-K Current report of material events | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 28, 2026 | View on SEC |
Material Events
8-K Legal Issue January 9, 2026
Medium Impact
- Tempest Therapeutics received a notice from Nasdaq for not holding its annual stockholder meeting within the required timeframe.
- The company's fiscal year ended December 31, 2024, meaning the 2025 Annual Meeting was due by December 31, 2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.